NASDAQ:KROS

Keros Therapeutics (KROS) Stock Price, News & Analysis

Keros Therapeutics logo
$11.04 -0.35 (-3.07%)
Closing price 11/20/2026 03:58 PM Eastern
Extended Trading
$11.07 +0.03 (+0.27%)
As of 11/20/2026 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

About Keros Therapeutics Stock (NASDAQ:KROS)

Advanced

Key Stats

Today's Range
$10.95
▼
$11.59
50-Day Range
$9.17
▼
$12.00
52-Week Range
$8.98
▼
$22.55
Volume
208,691 shs
Average Volume
188,630 shs
Market Capitalization
$216.60 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.00
Consensus Rating
Moderate Buy

Company Overview

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for serious medical conditions by modulating signaling pathways in the transforming growth factor beta (TGF-β) protein family. Its research has centered on disorders involving blood-cell production and muscle function.

The company’s pipeline has included elritercept, an investigational therapy designed to address anemia and other complications associated with blood disorders, as well as candidates developed for muscle-related conditions. These programs are investigational and are not approved treatments.

Founded in 2015 and based in Lexington, Massachusetts, Keros conducts research and clinical development with the aim of serving patients in multiple markets. Cofounder Jasbir Seehra has served as the company’s chief executive officer.

AI Generated. May Contain Errors.

Keros Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

KROS MarketRank™: 
2.902170887835 of 5 stars

Keros Therapeutics scored higher than 58% of companies evaluated by MarketBeat, and ranked 277th out of 845 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Keros Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 1 strong buy rating, 3 buy ratings, 2 hold ratings, and 1 sell rating.

  • Upside Potential

    Keros Therapeutics has a consensus price target of $20.00, representing about 81.2% upside from its current price of $11.04.

  • Amount of Analyst Coverage

    Keros Therapeutics has only been the subject of 2 research reports in the past 90 days.

  • Read more about Keros Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Keros Therapeutics are expected to decrease in the coming year, from ($3.36) to ($5.12) per share.

  • Price to Book Value per Share Ratio

    Keros Therapeutics has a P/B Ratio of 0.78. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    6.27% of the float of Keros Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Keros Therapeutics has a short interest ratio ("days to cover") of 7.06.
  • Change versus previous month

    Short interest in Keros Therapeutics has recently decreased by 4.45%, indicating that investor sentiment is improving.
  • Dividend Yield

    Keros Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Keros Therapeutics does not have a long track record of dividend growth.

  • News Sentiment

    Keros Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.
  • News Coverage This Week

    MarketBeat has tracked 8 news articles for Keros Therapeutics this week, compared to 2 articles on an average week.
  • Search Interest

    2 people have searched for KROS on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • MarketBeat Follows

    3 people have added Keros Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Keros Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $12,206.00 in company stock.

  • Percentage Held by Insiders

    12.60% of the stock of Keros Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    71.56% of the stock of Keros Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Keros Therapeutics' insider trading history.
Receive KROS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Keros Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

KROS Stock News Headlines

Why I'm selling my Snapback Indicator for just $7
For Black Friday, Base Camp Trading's Thomas Wood is offering lifetime access to his proprietary Snapback Indicator for a single $7 payment. Others previously paid $500. The indicator flashes a Crash Alert as a cue to exit or go short, and a Bull Run Alert as a cue to buy or go long. No strings attached, and Wood says there is an unusual reason behind the steep discount.tc pixel
FY2026 EPS Forecast for Keros Therapeutics Lifted by Analyst
See More Headlines

KROS Stock Analysis - Frequently Asked Questions

Keros Therapeutics' stock was trading at $20.36 at the beginning of 2026. Since then, KROS shares have decreased by 45.8% and is now trading at $11.04.

Keros Therapeutics, Inc. (NASDAQ:KROS) posted its earnings results on Thursday, November, 5th. The company reported $0.70 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.96) by $1.66. The business earned $40.01 million during the quarter, compared to analysts' expectations of $14.76 million. Keros Therapeutics had a negative trailing twelve-month return on equity of 21.85% and a negative net margin of 256.60%.

Keros Therapeutics' Board of Directors approved a stock repurchase program on Wednesday, September 9th 2026, which authorizes the company to buy back $5 million in shares, according to EventVestor. This means that the company could buy up to 2.3% of its shares through open market purchases. Shares buyback programs are generally a sign that the company's management believes its stock is undervalued.

Keros Therapeutics (KROS) raised $90 million in an initial public offering on Wednesday, April 8th 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Jefferies, SVB Leerink and Piper Sandler acted as the underwriters for the IPO and H.C. Wainwright & Co. was co-manager.

Top institutional shareholders of Keros Therapeutics include Nantahala Capital Management LLC (7.59%), State Street Corp (2.76%), Goldman Sachs Group Inc. (1.30%) and Empowered Funds LLC (0.67%). Insiders that own company stock include Carl L Gordon, Carl L Gordon, Annita Tanini, Lorena Raquel Lerner, Jean Jacques Bienaime, Anne Prener, Charles W Newton, Julius Knowles, Nima Farzan, Alpna Seth, Pontifax Management 4 GP (20 and Adar1 Capital Management, Llc.
View institutional ownership trends
.

Shares of KROS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Keros Therapeutics investors own include NVIDIA (NVDA), Oracle (ORCL), Taiwan Semiconductor Manufacturing (TSM), Advanced Micro Devices (AMD), Broadcom (AVGO), Marvell Technology (MRVL) and Micron Technology (MU).

Company Calendar

Last Earnings
11/05/2026
Today
11/21/2026
Fiscal Year End
12/31/2026

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Biotechnology
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:KROS
CIK
1664710
Fax
N/A
Employees
92
Year Founded
2015

Price Target and Rating

High Price Target
$23.00
Low Price Target
$18.00
Potential Upside/Downside
+81.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.57
Research Coverage
7 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.82)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$87.01 million
Net Margins
-256.60%
Pretax Margin
-153.25%
Return on Equity
-21.85%
Return on Assets
-19.83%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
18.14
Quick Ratio
18.14

Sales & Book Value

Annual Sales
$244.06 million
Price / Sales
0.89
Cash Flow
$5.00 per share
Price / Cash Flow
2.21
Book Value
$14.22 per share
Price / Book
0.78

Miscellaneous

Outstanding Shares
19,620,000
Free Float
17,151,000
Market Cap
$216.60 million
Optionable
Optionable
Beta
1.13

Social Links

7 Stocks That Could Be Bigger Than Tesla, NVIDIA, and Google Cover

Could the next Tesla, NVIDIA, and Google be hiding in plain sight? Discover seven growth stocks with the potential to become tomorrow's market giants, fueled by breakthroughs in AI, nuclear energy, cybersecurity, and more.

Get This Free Report

This page (NASDAQ:KROS) was last updated on 11/20/2026 by MarketBeat.com Staff.
From Our Partners